Related Experiment Video
Updated: Aug 5, 2026
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Seroprotection Against Mumps in MMR Vaccinated Children Aged 9-12 Years: A Cross-Sectional Study
Dhairya Bansal1, Aaradhana2, Bineeta Kashyap3
1Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India.
Insights
A single measles-mumps-rubella (MMR) vaccine dose in childhood provides mumps seroprotection in 84.8% of 9-12 year olds. Older children were more likely to lose immunity, indicating a need for further study on vaccine durability.
Area of Science:
- Immunology
- Vaccinology
- Pediatric Infectious Diseases
Background:
- The measles-mumps-rubella (MMR) vaccine is crucial for preventing childhood diseases.
- Understanding the long-term effectiveness of a single MMR dose against mumps is essential for public health strategies in India.
Purpose of the Study:
- To determine the proportion of children aged 9-12 years with protective mumps antibody titers after one MMR vaccine dose.
- To investigate the relationship between seroprotection and child's clinicodemographic profile.
Main Methods:
- A cross-sectional study in Delhi included 86 children aged 9-12 years with documented single MMR vaccination at 16-24 months.
- Serum mumps-specific IgG antibodies were measured using ELISA; seroprotection was defined as titers ≥ 22 RU/mL.
- Chi-square or Fisher's exact tests assessed associations between seroprotection and variables like age, sex, and nutritional status.
Main Results:
- 84.8% of children exhibited seroprotective mumps antibody titers.
- The median mumps-specific IgG titer was 97.6 RU/mL.
- Children over 10 years old were significantly more likely to be seronegative (OR 3.99, P=0.039).
Conclusions:
- A single MMR vaccine dose confers mumps seroprotection in a majority of children up to age 12.
- Declining immunity in older children warrants further research into the durability of mumps protection.
- Findings support ongoing evaluation of MMR vaccination strategies in India.
Objectives:
To estimate the proportion of children aged 9-12 years with seroprotective antibody titers against mumps following a single dose of measles-mumps-rubella (MMR) vaccine administered in early childhood, and to explore the association between seroprotection and clinicodemographic profile.
Methods:
A cross-sectional study was conducted at a tertiary hospital in Delhi between April 2024 and August 2025. Children aged 9-12 years with a documented receipt of a single dose of MMR vaccine at 16-24 months of age were recruited. Two mL of venous blood was collected and analyzed for serum mumps-specific IgG antibodies using enzyme-linked immunosorbent assay (ELISA), with seroprotection defined as mumps antibody titers ≥ 22 RU/mL. The association between seroprotection and demographic and clinical variables, including age, sex, age at vaccination, and nutritional status, was assessed using the chi-square test or Fisher's exact test.
Results:
Eighty-six children (48% males) aged 9-12 years [mean (SD) 10.35 (1.04) years] were enrolled. Overall, 84.8% demonstrated seroprotective antibody titers against mumps. The median (q1, q3) mumps-specific IgG titer was 97.6 (46.1, 144.9) RU/mL. Children aged > 10 years were significantly more likely to be seronegative compared to younger children (OR 3.99, 95% CI 1.07, 14.92, P = 0.039).
Conclusion:
Nearly 85% of children who had received a single MMR dose at 16-24 months of age had seroprotective mumps antibody titers at 9-12 years. The findings highlight the need for larger community-based studies on the durability of mumps immunity and add to the accumulating evidence informing future MMR vaccination strategies in India.
Related Concept Videos
01:29Respiratory Syncytial Virus Disease
01:17Poliomyelitis